Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.66 |
| ▸ | CES1 | P23141 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | THRA | P10827 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6260279 | 0.92 | ALDH1A1 (0.77) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL11060904 | 0.89 | KMT2A (0.73) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL8544673 | 0.87 | ALDH1A1 (0.72) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL6995692 | 0.85 | KMT2A (0.67) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL11068063 | 0.85 | KMT2A (0.74) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL297043 | 0.84 | KMT2A (0.71) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL29508878 | 0.84 | KMT2A (0.71) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL11064012 | 0.83 | CYP1A2 (0.70) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL28895007 | 0.83 | POLB (0.53) | KMT2AMEN1ALDH1A1HPGDMAPT | |
| SCHEMBL432613 | 0.83 | KMT2A (0.69) | KMT2AMEN1ALDH1A1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104710367-A | Method for synthesizing enzalutamide | UNIV CHINA PHARMA | 2015-06-17 | — | — | CN | claimed |
| EP-4695230-A1 | PROTEASE INHIBITORS AND USES THEREOF | Westlake Pharmaceuticals (Hangzhou) Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-12528797-B2 | Heterocyclic compounds for medical treatment | C4 THERAPEUTICS, INC. | 2026-01-20 | — | — | US | disclosed |
| WO-2024212101-A1 | PROTEASE INHIBITORS AND USES THEREOF | WESTLAKE PHARMACEUTICALS (HANGZHOU) CO., LTD. (CN) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2023217879-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| US-20230160001-A1 | NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-05-25 | — | — | US | disclosed |
| US-4160095-A | PROSTAGLANDINS; ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-07-03 | — | — | US | disclosed |
| US-4157441-A | PROSTAGLANDINS, ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-06-05 | — | — | US | disclosed |
| US-4151351-A | PROSTAGLANDINS, ANTIINFLAMMATORY | THE UPJOHN COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528797-B2 | Heterocyclic compounds for medical treatment | CRBN, CUL2, ADRM1 | KMT2A 1155/4885MEN1 822/4885ALDH1A1 2849/4885 |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | KMT2A 821/4885MEN1 940/4885ALDH1A1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.